The paper reports on the Phase 1a dose escalation data of IO-202 as monotherapy and in combination with azacitidine (AZA) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and R/R chronic myelomonocytic leukemia (CMML), as well as the Phase 1b dose expansion data of IO-202 combined with AZA for the treatment of hypomethylating agent (HMA)-naïve CMML.
Immune-Onc today announced that the first patient has been dosed with IO-108 in a global clinical collaboration with Roche. The Phase 1b/2 trial is designed to evaluate IO-108, a first-in-class antibody targeting LILRB2 (also known as ILT4), in combination with Roche’s atezolizumab and bevacizumab as a potential first-line treatment for patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC).
Immune-Onc presented updated data from its Phase 1b expansion cohort evaluating IO-202, a first-in-class anti-LILRB4 antibody, in combination with azacitidine (AZA) in patients with chronic myelomonocytic leukemia (CMML). These new findings were highlighted in an oral presentation at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, California.
Immune-Onc announced the publication of Phase 1 dose-escalation study results of IO-108, its first-in-class antibody targeting LILRB2 (also known as ILT4), in the Journal for ImmunoTherapy of Cancer (JITC), the peer-reviewed, online journal of the Society for Immunotherapy of Cancer (SITC).
Immune-Onc Therapeutics to Present Additional Positive Interim Data From IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress
Immune-Onc Therapeutics to Present Additional Positive Interim Data From IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at the 2024 EHA Annual Congress
Phase 1 study of IO-202 in combination with azacitidine currently enrolling newly diagnosed CMML patients
Collaboration to evaluate IO-108 in combination with atezolizumab (Tecentriq®) and bevacizumab (Avastin®) as a potential first-line therapy for hepatocellular carcinoma